Clinical Trial Update: Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris [Phase 3]

View source ↗

Summary

Phase 3 multicenter, randomized, double-blind trial evaluating the efficacy and safety of CD0271 0.3%/CD1579 2.5% topical gel in acne vulgaris. Results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• CD0271 0.3% / CD1579 2.5% Topical Gel

Snippet

Sponsor: Galderma R&D | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2016-09-09